Table 4.

Summary of Studies for DOACs in Bioprosthetic Heart Valves/TAVI without Concurrent Indication for Anticoagulation.

Drug	Studies in bioprosthetics/ TAVI without concurrent indication for anticoagulation
Rivaroxaban	• Possible ↑ in the risk of death, thromboembolism, and bleeding for patients undergoing TAVI (within 1 to 7 days), compared to standard of care, in GALILEO 2020 46
Apixaban	• Possible ↑ in non-cardiovascular mortality for patients undergoing TAVI (duration from TAVI to initiation of antithrombotics unknown), compared to standard of care, in ATLANTIS 2021 34
Edoxaban	• Inconclusive short-term data for patients undergoing surgical repair/replacement with bioprosthetic valve (not TAVI), in select patients, compared to standard of care, x 3 months in ENAVLE 2021 47
Dabigatran	• No data

Abbreviation: direct-acting oral anticoagulant (DOAC), transcatheter aortic valve implantation (TAVI).